Literature DB >> 28252004

Breast cancer: Utidelone: burden relief in pretreated women.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Year:  2017        PMID： 28252004     DOI： 10.1038/nrclinonc.2017.29

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Utidelone plus capecitabine versus capecitabine alone for heavily pretreated metastatic breast cancer refractory to anthracyclines and taxanes: a multicentre, open-label, superiority, phase 3, randomised controlled trial.

Authors:  Pin Zhang; Tao Sun; Qingyuan Zhang; Zhongyu Yuan; Zefei Jiang; Xiao Jia Wang; Shude Cui; Yuee Teng; Xi-Chun Hu; Junlan Yang; Hongming Pan; Zhongsheng Tong; Huiping Li; Qiang Yao; Yongsheng Wang; Yongmei Yin; Ping Sun; Hong Zheng; Jing Cheng; Jinsong Lu; Baochun Zhang; Cuizhi Geng; Jian Liu; Roujun Peng; Min Yan; Shaohua Zhang; Jian Huang; Li Tang; Rongguo Qiu; Binghe Xu
Journal:  Lancet Oncol       Date:  2017-02-11       Impact factor: 41.316
  1 in total
  2 in total

1.  Ganglioside Monosialic Acid Alleviates Peripheral Neuropathy Induced by Utidelone Plus Capecitabine in Metastatic Breast Cancer From a Phase III Clinical Trial.

Authors:  Junnan Xu; Yan Wang; Cui Jiang; Hui Cao; Junhan Jiang; Binghe Xu; Tao Sun
Journal:  Front Oncol       Date:  2020-10-09       Impact factor: 6.244

2.  Utidelone inhibits growth of colorectal cancer cells through ROS/JNK signaling pathway.

Authors:  Fuli Li; Tinglei Huang; Yao Tang; Qingli Li; Jianzheng Wang; Xiaojiao Cheng; Wenhui Zhang; Baiwen Zhang; Cong Zhou; Shuiping Tu
Journal:  Cell Death Dis       Date:  2021-04-01       Impact factor: 8.469
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.